Differential expression of E-cadherin and P-cadherin in pT3 prostate cancer: correlation with clinical and pathological features
- 43 Downloads
Cadherins seem to play and important role in prostate cancer (PCa) progression. E-cadherin loss of expression has been associated with poor prognosis; P-cadherin’s role is still elusive. Although pT3 PCa is often considered “high-risk cancer,” it does not exhibit an uniformly poor prognosis. Herein, we assessed the prognostic value and survival impact of E-cadherin and P-cadherin immunoexpression in pT3 PCa. Radical prostatectomy (RP) specimens from 102 pT3 PCa patients treated between 1991 and 2014 in a single institution were designated for E-cadherin and P-cadherin immunoexpression analysis. A representative block from each specimen was selected for tissue micro-array (TMA) construction, using 3 cores per case. E-cadherin immunoexpression was assessed via a digital image analysis system. For P-cadherin, scoring criteria for HER2 in gastric cancer were used. Clinical records of all patients were reviewed for baseline clinical/pathologic characteristics and follow-up data. E-cadherin-low PCa patients displayed worse disease-specific survival (DSS), although not reaching statistical significance (HR 2.65, 95%CI 0.81–7.88). However, considering the pT3b group only, those with low E-cadherin immunoexpression displayed significantly worse overall-survival (OS) and DSS (HR 3.69, 95%CI 1.18–11.50; HR 5.90, 95%CI 1.40–24.81). No significant differences in survival were found for P-cadherin differential immunoexpression. Furthermore, an association between E-cadherin and P-cadherin immunoexpression (p = 0.019) was found, as among E-cadherin-low PCa, 96.6% were P-cadherin negative. We demonstrated that low E-cadherin immunoexpression discriminates among pT3b PCa patients those with poorer survival and which might benefit from specific therapy. The role of P-cadherin in PCa seems context-dependent deserving further investigation.
KeywordsProstate cancer E-cadherin P-cadherin Survival
CF, JL, and RH designed the study; CF, JL, and PL performed technical procedures and acquired pathological and clinical data; CF, JL, CJ and RH analyzed and interpreted data; CF, JL, and LA performed statistical analysis; CF drafted the manuscript; all authors reviewed and approved the final version of the manuscript. All individuals listed as co-authors of the manuscript have significantly contributed to this study.
This study was supported by project CI-IPOP-17-2015 (Epigenetic signature of prostate cancer stem cells) funded by the Research Centre of Portuguese Oncology Institute of Porto. JL is supported by an FCT—Fundação para a Ciência e Tecnologia—fellowship (grant number SFRH/BD/132751/2017).
Compliance with ethical standards
This study was approved by the institutional ethics committee of Portuguese Oncology Institute Porto (Comissão de Ética para a Saúde do IPO Porto—CES 235/2017).
Conflict of interest
The authors declare that they have no conflict of interest.
- 5.Stephenson RA, Smart CR, Mineau GP, James BC, Janerich DT, Dibble RL (1996) The fall in incidence of prostate carcinoma. On the down side of a prostate specific antigen induced peak in incidence—data from the Utah Cancer registry. Cancer 77(7):1342–1348. https://doi.org/10.1002/(SICI)1097-0142(19960401)77:7<1342::AID-CNCR18>3.0.CO;2-1 CrossRefPubMedGoogle Scholar
- 6.Tsaur I, Noack A, Makarevic J, Oppermann E, Waaga-Gasser AM, Gasser M, Borgmann H, Huesch T, Gust KM, Reiter M, Schilling D, Bartsch G, Haferkamp A, Blaheta RA (2015) CCL2 chemokine as a potential biomarker for prostate cancer: a pilot study. Cancer Res Treat 47(2):306–312. https://doi.org/10.4143/crt.2014.015 CrossRefPubMedGoogle Scholar
- 12.Bauer JJ, Connelly RR, Seterhenn IA, Deausen J, Srivastava S, McLeod DG, Moul JW (1998) Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. J Urol 159(3):929–933CrossRefPubMedGoogle Scholar
- 13.Drivalos A, Chrisofos M, Efstathiou E, Kapranou A, Kollaitis G, Koutlis G, Antoniou N, Karanastasis D, Dimopoulos MA, Bamias A (2016) Expression of α5-integrin, α7-integrin, Ε-cadherin, and N-cadherin in localized prostate cancer. Urol Oncol 34(4):165.e111–165.e168. https://doi.org/10.1016/j.urolonc.2015.10.016 CrossRefGoogle Scholar
- 16.Yossepowitch O, Eggener SE, Bianco FJ, Carver BS, Serio A, Scardino PT, Eastham JA (2007) Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 178(2):493–499; discussion 499. https://doi.org/10.1016/j.juro.2007.03.105 CrossRefPubMedGoogle Scholar
- 18.Soler AP, Harner GD, Knudsen KA, McBrearty FX, Grujic E, Salazar H, Han AC, Keshgegian AA (1997) Expression of P-cadherin identifies prostate-specific-antigen-negative cells in epithelial tissues of male sexual accessory organs and in prostatic carcinomas. Implications for prostate cancer biology. Am J Pathol 151(2):471–478PubMedPubMedCentralGoogle Scholar
- 26.Lazari P, Poulias H, Gakiopoulou H, Thomopoulou GH, Barbatis C, Lazaris AC (2013) Differential immunohistochemical expression of CD44s, E-cadherin and β-catenin among hyperplastic and neoplastic lesions of the prostate gland. Urol Int 90(1):109–116. https://doi.org/10.1159/000345057 CrossRefPubMedGoogle Scholar
- 28.Uchikado Y, Okumura H, Ishigami S, Setoyama T, Matsumoto M, Owaki T, Kita Y, Natsugoe S (2011) Increased slug and decreased E-cadherin expression is related to poor prognosis in patients with gastric cancer. Gastric Cancer 14(1):41–49. https://doi.org/10.1007/s10120-011-0004-x CrossRefPubMedGoogle Scholar
- 32.Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Wiegel T, Zattoni F, Mottet N, EAo U (2014) EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65(2):467–479. https://doi.org/10.1016/j.eururo.2013.11.002 CrossRefPubMedGoogle Scholar
- 33.Tang LH, Berlin J, Branton P, Burgart LJ, Carter DK, Compton CC, Fitzgibbons P, Frankel WL, Jessup J, Kakar S, Minsky B, Nakhleh R, Washington K (2013) Protocol for the examination of specimens from patients with carcinoma of the stomach. Gastrointestinal - Stomach, vol Stomach 18.104.22.168. College of American Pathologists (CAP). Based on AJCC/UICC TNM, 7th edition. http://www.cap.org/cancerprotocols. Accessed 1 Oct 2017
- 35.Howlader N, Noone A, Krapcho M, Miller D, Bishop K, Kosary C, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis D, Chen H, Feuer E, Cronin K (2017) SEER Cancer Statistics Review, 1975–2014, National Cancer Institute. https://seer.cancer.gov/csr/1975_2014/, based on November 2016 SEER data submission, posted to the SEER web site, April 2017. Bethesda, MD
- 36.Epstein JI, Zelefsky MJ, Sjoberg DD, Nelson JB, Egevad L, Magi-Galluzzi C, Vickers AJ, Parwani AV, Reuter VE, Fine SW, Eastham JA, Wiklund P, Han M, Reddy CA, Ciezki JP, Nyberg T, Klein EA (2016) A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 69(3):428–435. https://doi.org/10.1016/j.eururo.2015.06.046 CrossRefPubMedGoogle Scholar
- 37.Berney DM, Beltran L, Fisher G, North BV, Greenberg D, Møller H, Soosay G, Scardino P, Cuzick J (2016) Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome. Br J Cancer 114(10):1078–1083. https://doi.org/10.1038/bjc.2016.86 CrossRefPubMedPubMedCentralGoogle Scholar
- 39.Jeong BC, Chalfin HJ, Lee SB, Feng Z, Epstein JI, Trock BJ, Partin AW, Humphreys E, Walsh PC, Han M (2015) The relationship between the extent of extraprostatic extension and survival following radical prostatectomy. Eur Urol 67(2):342–346. https://doi.org/10.1016/j.eururo.2014.06.015 CrossRefPubMedGoogle Scholar
- 42.van Oort IM, Tomita K, van Bokhoven A, Bussemakers MJ, Kiemeney LA, Karthaus HF, Witjes JA, Schalken JA (2007) The prognostic value of E-cadherin and the cadherin-associated molecules alpha-, beta-, gamma-catenin and p120ctn in prostate cancer specific survival: a long-term follow-up study. Prostate 67(13):1432–1438. https://doi.org/10.1002/pros.20626 CrossRefPubMedGoogle Scholar
- 43.Behnsawy HM, Miyake H, Harada K, Fujisawa M (2013) Expression patterns of epithelial-mesenchymal transition markers in localized prostate cancer: significance in clinicopathological outcomes following radical prostatectomy. BJU Int 111(1):30–37. https://doi.org/10.1111/j.1464-410X.2012.11551.x CrossRefPubMedGoogle Scholar
- 44.Whiteland H, Spencer-Harty S, Thomas DH, Davies C, Morgan C, Kynaston H, Bose P, Fenn N, Lewis PD, Bodger O, Jenkins S, Doak SH (2013) Putative prognostic epithelial-to-mesenchymal transition biomarkers for aggressive prostate cancer. Exp Mol Pathol 95(2):220–226. https://doi.org/10.1016/j.yexmp.2013.07.010 CrossRefPubMedGoogle Scholar
- 46.Paredes J, Figueiredo J, Albergaria A, Oliveira P, Carvalho J, Ribeiro AS, Caldeira J, Costa AM, Simões-Correia J, Oliveira MJ, Pinheiro H, Pinho SS, Mateus R, Reis CA, Leite M, Fernandes MS, Schmitt F, Carneiro F, Figueiredo C, Oliveira C, Seruca R (2012) Epithelial E- and P-cadherins: role and clinical significance in cancer. Biochim Biophys Acta 1826(2):297–311. https://doi.org/10.1016/j.bbcan.2012.05.002 PubMedGoogle Scholar
- 50.Gravdal K, Halvorsen OJ, Haukaas SA, Akslen LA (2007) A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer. Clin Cancer Res 13(23):7003–7011. https://doi.org/10.1158/1078-0432.CCR-07-1263 CrossRefPubMedGoogle Scholar
- 53.Imai K, Hirata S, Irie A, Senju S, Ikuta Y, Yokomine K, Harao M, Inoue M, Tsunoda T, Nakatsuru S, Nakagawa H, Nakamura Y, Baba H, Nishimura Y (2008) Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers. Clin Cancer Res 14(20):6487–6495. https://doi.org/10.1158/1078-0432.CCR-08-1086 CrossRefPubMedGoogle Scholar